We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




VedaBio Partners With Mammoth Biosciences to Expand CRISPR-Based Diagnostic Technologies

By LabMedica International staff writers
Posted on 16 Sep 2025

VedaBio (San Diego, CA, USA) has entered into a non-exclusive license agreement with Mammoth Biosciences (Brisbane, CA, USA) for the use of select CRISPR-based technologies in diagnostic applications. More...

VedaBio harnesses cutting-edge CRISPR technology to deliver rapid, accurate, and accessible diagnostics. The company is dedicated to advancing the next generation of molecular diagnostics to improve healthcare outcomes. Mammoth Biosciences focuses on leveraging its proprietary ultracompact CRISPR systems to develop potential long-term curative therapies for patients with life-threatening and debilitating diseases.

The agreement provides VedaBio with access to foundational CRISPR intellectual property, enabling the company to accelerate development of purpose-built diagnostic solutions. This alliance reinforces VedaBio’s commitment to building a next-generation platform designed for speed and accuracy, with an initial focus on decentralized healthcare settings. The company’s ultracompact systems are designed to be more specific and enable in vivo gene editing in difficult-to-reach tissues, utilizing both nuclease applications and new editing modalities beyond double-stranded breaks, including base editing, reverse transcriptase editing, and epigenetic editing.

CRISPR-based detection allows for highly specific molecular recognition. When integrated with VedaBio’s platform, it opens the door to rapid, accurate diagnostics that can be deployed in urgent care, outpatient clinics, and other decentralized settings, without sacrificing sensitivity or specificity. With this partnership, VedaBio is uniquely positioned to lead the next wave of CRISPR-powered diagnostics, delivering solutions that are faster, more cost-effective, and better aligned with the realities of today’s healthcare landscape.

“We’re thrilled to work with the Mammoth team to help bring the full promise of CRISPR-based diagnostics to market,” said Frederic Sweeney, PhD, President and CEO of VedaBio. “This initiative expands the avenues for our proprietary platform and allows us to develop highly targeted, amplification-free molecular tests designed for real-world clinical needs.”

“Mammoth’s vision for diagnostics is to enable new solutions that have high impact on patient care,” added Janice Chen, PhD, Co-founder and CTO of Mammoth Biosciences. “The combination of Mammoth’s deep CRISPR intellectual property with VedaBio’s unique approach and product vision is an opportunity to deliver on the potential of CRISPR-based diagnostics.”

Related Links:
VedaBio 
Mammoth Biosciences


Gold Member
Automatic Hematology Analyzer
DH-800 Series
Portable Electronic Pipette
Mini 96
Hemodynamic System Monitor
OptoMonitor
Blood Glucose Test Strip
AutoSense Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: When assessing the same lung biopsy sample, research shows that only 18% of pathologists will agree on a TCMR diagnosis (Photo courtesy of Thermo Fisher)

Molecular Microscope Diagnostic System Assesses Lung Transplant Rejection

Lung transplant recipients face a significant risk of rejection and often require routine biopsies to monitor graft health, yet assessing the same biopsy sample can be highly inconsistent among pathologists.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.